发布求助
文献互助 智能选刊 最新文献

Breathe最新文献

筛选
英文 中文
Stage III NSCLC treatment options: too many choices. III 期 NSCLC 治疗方案：选择太多。
IF 2.3
Breathe Pub Date : 2024-10-01 DOI: 10.1183/20734735.0047-2024
Oke Dimas Asmara, Georgia Hardavella, Sara Ramella, René Horsleben Petersen, Ilona Tietzova, E Christiaan Boerma, Eric Daniel Tenda, Asmaa Bouterfas, Marjolein A Heuvelmans, Wouter H van Geffen
{"title":"Stage III NSCLC treatment options: too many choices.","authors":"Oke Dimas Asmara, Georgia Hardavella, Sara Ramella, René Horsleben Petersen, Ilona Tietzova, E Christiaan Boerma, Eric Daniel Tenda, Asmaa Bouterfas, Marjolein A Heuvelmans, Wouter H van Geffen","doi":"10.1183/20734735.0047-2024","DOIUrl":"10.1183/20734735.0047-2024","url":null,"abstract":"<p><p>Stage III nonsmall cell lung cancer (NSCLC) represents a wide range of tumour (T1 to T4) and nodal (N0 to N3) components, requiring variable management and a multidisciplinary approach. Recent advancements in minimally invasive techniques, molecular biology and novel drug discoveries have accelerated the refinement of stage III NSCLC management. The latest developments in staging include the forthcoming update of the nodal component in the 9th TNM (tumour-node-metastasis) edition, which emphasises the critical role for endobronchial ultrasonography in mediastinal staging. Recent treatment developments include the use of immunotherapy and targeted molecular therapy in both the neoadjuvant and adjuvant setting, either in combination with other modalities or used alone as consolidation. Surgical and radiotherapy advancements have further enhanced patient outcomes. These developments have significantly improved the prognosis for patients with stage III NSCLC. Fast-changing recommendations have also brought about a challenge, with clinicians facing a number of options to choose from. Therefore, a multimodal approach by a multidisciplinary team has become even more crucial in managing stage III NSCLC.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 3","pages":"240047"},"PeriodicalIF":2.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444491/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stage IV nonsmall cell lung cancer treatment: oligometastatic disease and disease progression, untangling the knot. IV 期非小细胞肺癌治疗：寡转移疾病与疾病进展，解开心结。
IF 2.3
Breathe Pub Date : 2024-08-27 eCollection Date: 2024-06-01 DOI: 10.1183/20734735.0039-2024
Tuğbanur Tezvergil, Ismini Kourouni, Adrien E Costantini, Diego Kauffmann-Guerrero, Torsten Gerriet Blum, Thierry Berghmans
{"title":"Stage IV nonsmall cell lung cancer treatment: oligometastatic disease and disease progression, untangling the knot.","authors":"Tuğbanur Tezvergil, Ismini Kourouni, Adrien E Costantini, Diego Kauffmann-Guerrero, Torsten Gerriet Blum, Thierry Berghmans","doi":"10.1183/20734735.0039-2024","DOIUrl":"10.1183/20734735.0039-2024","url":null,"abstract":"<p><p>Stage IV nonsmall cell lung cancer (NSCLC) is a heterogeneous group of patients for whom systemic therapy is decided based on tumour-biological cancer features (histology, PD-L1 expression, genomic alteration, metastatic sites) and patient characteristics (performance status, comorbidities). In most instances, some kind of systemic treatment is proposed, for which immunotherapy-based or targeted therapies are considered the standards of care in 2024. Oligometastatic NSCLC represents a specific concept during the biological spectrum from localised to metastatic disease in which only a limited number of metastatic sites can be documented. Based on this assumption, prospective and a few randomised phase II studies have been performed, which suggested that adding a local ablative treatment to the systemic one can be a new option for selected stage IV NSCLC. The European Organisation for Research and Treatment of Cancer (EORTC) and the European Society for Radiotherapy and Oncology (ESTRO) supported efforts to define oligometastatic NSCLC to unify the semantics within the thoracic oncology community. This article summarises the currently available data and emphasises the questions and perspectives in oligometastatic disease NSCLC in European patient cohorts.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 2","pages":"240039"},"PeriodicalIF":2.3,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11348918/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142079157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stage I and II nonsmall cell lung cancer treatment options. I 期和 II 期非小细胞肺癌治疗方案。
IF 2.3
Breathe Pub Date : 2024-08-27 eCollection Date: 2024-06-01 DOI: 10.1183/20734735.0219-2023
Georgia Hardavella, Dimitrios E Magouliotis, Roberto Chalela, Adam Januszewski, Fabio Dennstaedt, Paul Martin Putora, Alfred So, Angshu Bhowmik
{"title":"Stage I and II nonsmall cell lung cancer treatment options.","authors":"Georgia Hardavella, Dimitrios E Magouliotis, Roberto Chalela, Adam Januszewski, Fabio Dennstaedt, Paul Martin Putora, Alfred So, Angshu Bhowmik","doi":"10.1183/20734735.0219-2023","DOIUrl":"10.1183/20734735.0219-2023","url":null,"abstract":"<p><p>Chest radiography, computed tomography (CT) and positron emission tomography (PET)-CT are required for staging nonsmall cell lung cancers. Stage I cancers may be up to 4 cm in maximal diameter, with stage IA tumours being up to 3 cm and stage IB up to 4 cm. A lung cancer becomes stage II if the tumour is between 4 and ≤5 cm (stage IIA), or it spreads to ipsilateral peribronchial or hilar lymph nodes (stage IIB). Stage IA tumours should be surgically resected, ideally using minimally invasive methods. Lobectomy is usually performed, although some studies have shown good outcomes for sublobar resections. If surgery is not possible, stereotactic body radiotherapy is a good alternative. This involves delivering a few high-dose radiation treatments at very high precision. For stage IB to IIB disease, combinations of surgery, chemotherapy or immunotherapy and radiotherapy are used. There is evidence that neoadjuvant treatment (immunotherapy with nivolumab and chemotherapy for stage IB and II) optimises outcomes. Adjuvant chemotherapy with a platinum-based doublet (typically cisplatin+vinorelbine) should be offered for resected stage IIB tumours and considered for resected IIA tumours. Adjuvant pembrolizumab is used for stage IB-IIIA following resection and adjuvant platinum-based chemotherapy. Osimertinib may be used for resected stage IB to IIIA cancers which have relevant mutations (epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution). There are no fixed guidelines for follow-up, but most centres recommend 6-monthly CT scanning for the first 2-3 years after definitive treatment, followed by annual scans.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 2","pages":"230219"},"PeriodicalIF":2.3,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11348908/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142079156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the efficacy and advancements of medical pleurodesis: a comprehensive review of current research. 探索胸膜腔穿刺术的疗效和进展：当前研究的全面回顾。
IF 2.3
Breathe Pub Date : 2024-08-27 eCollection Date: 2024-06-01 DOI: 10.1183/20734735.0002-2024
Nadia Castaldo, Alberto Fantin, Michelangelo Palou-Schwartzbaum, Giovanni Viterale, Ernesto Crisafulli, Giulia Sartori, Avinash Aujayeb, Filippo Patrucco, Vincenzo Patruno
{"title":"Exploring the efficacy and advancements of medical pleurodesis: a comprehensive review of current research.","authors":"Nadia Castaldo, Alberto Fantin, Michelangelo Palou-Schwartzbaum, Giovanni Viterale, Ernesto Crisafulli, Giulia Sartori, Avinash Aujayeb, Filippo Patrucco, Vincenzo Patruno","doi":"10.1183/20734735.0002-2024","DOIUrl":"10.1183/20734735.0002-2024","url":null,"abstract":"<p><p>This narrative review aims to provide an overview of medical pleurodesis techniques, and their indications and potential adverse effects. Pleurodesis is a procedure performed with the aim of obliterating the pleural space. It has indications in the management of both malignant and benign pleural effusions and pneumothorax. Various nonsurgical techniques exist to perform pleurodesis. The scope of this work is to review the different nonsurgical techniques and their indications. This narrative review was performed checking scientific databases for medical literature, focusing especially on the data derived from randomised controlled trials. Pleurodesis is an effective method to manage pleural effusions and pneumothorax, and minimally invasive techniques are now frequently used with good results. Further research is needed to assess the efficacy of new treatments and the possibility of using different techniques in association.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 2","pages":"240002"},"PeriodicalIF":2.3,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11348907/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142079152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interventional bronchoscopy in lung cancer treatment. 介入性支气管镜在肺癌治疗中的应用。
IF 2.3
Breathe Pub Date : 2024-08-27 eCollection Date: 2024-06-01 DOI: 10.1183/20734735.0201-2023
Ales Rozman, Elzbieta Magdalena Grabczak, Vineeth George, Mateja Marc Malovrh, Helder Novais Bastos, Anna Trojnar, Simon Graffen, Eric Daniel Tenda, Georgia Hardavella
{"title":"Interventional bronchoscopy in lung cancer treatment.","authors":"Ales Rozman, Elzbieta Magdalena Grabczak, Vineeth George, Mateja Marc Malovrh, Helder Novais Bastos, Anna Trojnar, Simon Graffen, Eric Daniel Tenda, Georgia Hardavella","doi":"10.1183/20734735.0201-2023","DOIUrl":"10.1183/20734735.0201-2023","url":null,"abstract":"<p><p>Interventional bronchoscopy has seen significant advancements in recent decades, particularly in the context of lung cancer. This method has expanded not only diagnostic capabilities but also therapeutic options. In this article, we will outline various therapeutic approaches employed through either a rigid or flexible bronchoscope in multimodal lung cancer treatment. A pivotal focus lies in addressing central airway obstruction resulting from cancer. We will delve into the treatment of initial malignant changes in central airways and explore the rapidly evolving domain of early peripheral malignant lesions, increasingly discovered incidentally or through lung cancer screening programmes. A successful interventional bronchoscopic procedure not only alleviates severe symptoms but also enhances the patient's functional status, paving the way for subsequent multimodal treatments and thereby extending the possibilities for survival. Interventional bronchoscopy proves effective in treating initial cancerous changes in patients unsuitable for surgical or other aggressive treatments due to accompanying diseases. The key advantage of interventional bronchoscopy lies in its minimal invasiveness, effectiveness and favourable safety profile.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 2","pages":"230201"},"PeriodicalIF":2.3,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11348910/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142079153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lung cancer screening: where do we stand? 肺癌筛查：现状如何？
IF 2.3
Breathe Pub Date : 2024-08-27 eCollection Date: 2024-06-01 DOI: 10.1183/20734735.0190-2023
Georgia Hardavella, Armin Frille, Katherina Bernadette Sreter, Florence Atrafi, Uraujh Yousaf-Khan, Ferhat Beyaz, Fotis Kyriakou, Elena Bellou, Monica L Mullin, Sam M Janes
{"title":"Lung cancer screening: where do we stand?","authors":"Georgia Hardavella, Armin Frille, Katherina Bernadette Sreter, Florence Atrafi, Uraujh Yousaf-Khan, Ferhat Beyaz, Fotis Kyriakou, Elena Bellou, Monica L Mullin, Sam M Janes","doi":"10.1183/20734735.0190-2023","DOIUrl":"10.1183/20734735.0190-2023","url":null,"abstract":"<p><p>Lung cancer screening (LCS) programmes have emerged over recent years around the world. LCS programmes present differences in delivery, inclusion criteria and resource allocation. On a national scale, only a few LCS programmes have been fully established, but more are anticipated to follow. Evidence has shown that, in combination with a low-dose chest computed tomography scan, smoking cessation should be offered as part of a LCS programme for improved patient outcomes. Promising tools in LCS include further refined risk prediction models, the use of biomarkers, artificial intelligence and radiomics. However, these tools require further study and clinical validation is required prior to routine implementation.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 2","pages":"230190"},"PeriodicalIF":2.3,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11348916/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142079154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adjuvant immunotherapy and targeted therapy in early and locally advanced resectable lung cancer: expanding treatment tentacles? 早期和局部晚期可切除肺癌的辅助免疫疗法和靶向疗法：扩大治疗触角？
IF 2.3
Breathe Pub Date : 2024-08-27 eCollection Date: 2024-06-01 DOI: 10.1183/20734735.0035-2024
Evaggelos Fergadis, Amadea Heitmann, Theodore Tsaras, Georgia Hardavella
{"title":"Adjuvant immunotherapy and targeted therapy in early and locally advanced resectable lung cancer: expanding treatment tentacles?","authors":"Evaggelos Fergadis, Amadea Heitmann, Theodore Tsaras, Georgia Hardavella","doi":"10.1183/20734735.0035-2024","DOIUrl":"10.1183/20734735.0035-2024","url":null,"abstract":"<p><p>Adjuvant platinum-based chemotherapy has been the main treatment following surgical resection with curative intent in early and locally advanced nonsmall cell lung cancer (NSCLC) albeit with a 5% improvement in 5-year survival rates. Recent advances in biomarkers pave the way for targeted treatments and immunotherapy in a broader spectrum of patients with subsequently improved clinical outcomes. Targeted treatments and immunotherapy have established their place in the adjuvant setting of resected NSCLC.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 2","pages":"240035"},"PeriodicalIF":2.3,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11348914/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142079151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lung cancer: an update on the multidisciplinary approach from screening to palliative care. 肺癌：从筛查到姑息治疗的多学科方法的最新进展。
IF 2.3
Breathe Pub Date : 2024-08-27 eCollection Date: 2024-06-01 DOI: 10.1183/20734735.0117-2024
Georgia Hardavella, Joanna Chorostowska-Wynimko, Torsten Gerriet Blum
{"title":"Lung cancer: an update on the multidisciplinary approach from screening to palliative care.","authors":"Georgia Hardavella, Joanna Chorostowska-Wynimko, Torsten Gerriet Blum","doi":"10.1183/20734735.0117-2024","DOIUrl":"10.1183/20734735.0117-2024","url":null,"abstract":"<p><p><b>This issue of <i>Breathe</i> aims to provide a succinct overview of the current state of play in various aspects in thoracic oncology</b> https://bit.ly/3XQexmp.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 2","pages":"240117"},"PeriodicalIF":2.3,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11348915/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142079155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A scoping review of lung cancer surgery with curative intent: workup, fitness assessment, clinical outcomes. 以治愈为目的的肺癌手术范围综述：准备工作、体能评估、临床结果。
IF 2.3
Breathe Pub Date : 2024-08-27 eCollection Date: 2024-06-01 DOI: 10.1183/20734735.0046-2024
Georgia Hardavella, Federica Carlea, Ioannis Karampinis, Alexandro Patirelis, Kalliopi Athanasiadi, Dimitrios Lioumpas, Joana Rei, Lucas Hoyos, Georgios Benakis, Edward Caruana, Eugenio Pompeo, Stefano Elia
{"title":"A scoping review of lung cancer surgery with curative intent: workup, fitness assessment, clinical outcomes.","authors":"Georgia Hardavella, Federica Carlea, Ioannis Karampinis, Alexandro Patirelis, Kalliopi Athanasiadi, Dimitrios Lioumpas, Joana Rei, Lucas Hoyos, Georgios Benakis, Edward Caruana, Eugenio Pompeo, Stefano Elia","doi":"10.1183/20734735.0046-2024","DOIUrl":"10.1183/20734735.0046-2024","url":null,"abstract":"<p><p>Lung cancer surgery with curative intent has significantly developed over recent years, mainly focusing on minimally invasive approaches that do not compromise medical efficiency and ensure a decreased burden on the patient. It is directly linked with an efficient multidisciplinary team that will perform appropriate pre-operative assessment. Caution is required in complex patients with several comorbidities to ensure a meaningful and informed thoracic surgery referral leading to optimal patient outcomes.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 2","pages":"240046"},"PeriodicalIF":2.3,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11348919/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142079150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Two women with unexplained dyspnoea: removing the blame game from the lungs. 两名不明原因呼吸困难的妇女：从肺部消除指责游戏。
IF 2.3
Breathe Pub Date : 2024-08-27 eCollection Date: 2024-06-01 DOI: 10.1183/20734735.0029-2024
Eirini Vasarmidi, Irini Lambiri, Eirini Foteinaki, Vaia Stamatopoulou, Ioanna Mitrouska, Georgios Pitsidianakis, Alexandros Patrianakos, Anthoula Plevritaki, Stylianos Michelakis, Vasilis Amargianitakis, Georgios Prinianakis, Sophia Schiza, Nikolaos Tzanakis
{"title":"Two women with unexplained dyspnoea: removing the blame game from the lungs.","authors":"Eirini Vasarmidi, Irini Lambiri, Eirini Foteinaki, Vaia Stamatopoulou, Ioanna Mitrouska, Georgios Pitsidianakis, Alexandros Patrianakos, Anthoula Plevritaki, Stylianos Michelakis, Vasilis Amargianitakis, Georgios Prinianakis, Sophia Schiza, Nikolaos Tzanakis","doi":"10.1183/20734735.0029-2024","DOIUrl":"https://doi.org/10.1183/20734735.0029-2024","url":null,"abstract":"<p><p><b>Hypoxaemia due to right-to-left atrial shunt with normal pressures in the right heart cavities represents an underdiagnosed condition. A systematic approach to hypoxaemic respiratory failure based on pathophysiology can lead to an accurate diagnosis.</b> https://bit.ly/4bTP8fJ.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 2","pages":"240029"},"PeriodicalIF":2.3,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11356787/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142104592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信